RGU Research – Alternative Cysteamine Delivery Systems

We are grateful to the Cystinosis Research Team at the Robert Gordon University Aberdeen, and in particular researcher, Barbara Buchan, for allowing us to publish their research poster presentation. The poster was presented at the APS Conference in Nottingham.

CystagonTM, the primary medicine for treating Cystinosis, must be administered every 6 hours and the team are looking at alternative delivery mechanisms for Cysteamine (the key ingredient of Cystagon) to increase its effectiveness and reduce the frequency of administration. The Cystinosis Foundation UK has been providing financial support to the team to enable Barbara to undertake this research.

Their research includes looking at delivering Cysteamine as a dry powder to the lungs, in a manner not too dissimilar to inhalers used by asthmatics. It is believed the large surface area of the lungs will help achieve a more efficient delivery of Cysteamine throughout the body.

View Poster Presentation (requires Adobe Reader)

Comments are closed.

QUALIFY-US Study Participants are needed for the testing of a newly developed questionnaire to measure the [...] Read more...
CNE International Conference 2024 Cystinosis Network Europe and Cystinosis Foundation UK are delighted to announce the 2024 [...] Read more...
Cystinosis Comic Book Series by Artist Kevin McCalla The Cystinosis Research Network in the US has teamed up with Kevin McCalla, a young artist who [...] Read more...
Summer 2023 Newsletter The Summer 2023 edition of our email newsletter is available to view at the link below. CFUK [...] Read more...
All website content copyright Cystinosis Foundation UK (Charity No.1074885) 1997-2013, except where explicitly stated.
Data Protection Act Registration Number: Z9880997. Please refer to our terms and conditions and our privacy policy.